AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral discharge on examination
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral pathogens detected in men without clinical features
Number of subjects: 615
Study 20004957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing technique
Number of subjects: 20
Study 20004957 — intervention group
Group type: COMPARATOR
Intervention: Traditional radical hysterectomy
Number of subjects: 20
Study 18575162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 0.1 mg morphine, 0.015 mg fentanyl and 15 mg hyperbaric bupivacaine (Group I, n = 20)
Number of subjects: 40
Study 18575162 — intervention group
Group type: COMPARATOR
Intervention: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II, n = 20)
Number of subjects: 40
Study 18575162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 0.1 mg morphine, 0.015 mg fentanyl and 15 mg hyperbaric bupivacaine (Group I)
Number of subjects: 40
Study 18575162 — intervention group
Group type: COMPARATOR
Intervention: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II)
Number of subjects: 40
Study 18575162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Group I and Group II)
Number of subjects: 40
Study 16093971 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate (HAL) fluorescence cystoscopy
Number of subjects: 146
Study 16093971 — intervention group
Group type: COMPARATOR
Intervention: Standard white light cystoscopy
Number of subjects: 146
Study 12616845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0
Study 12616845 — intervention group
Group type: COMPARATOR
Intervention: Pharmacoepidemiological studies
Number of subjects: 0
Study 12616845 — intervention group
Group type: COMPARATOR
Intervention: National registry for drug-induced QT prolongation
Number of subjects: 0
Study 10561636 — intervention group
Group type: COMPARATOR
Intervention: 50‐g glucose beverage
Number of subjects: 160
Study 10561636 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 jelly beans (50 g simple carbohydrate)
Number of subjects: 160
Study 10561636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sugar sources
Number of subjects: 160
Study 8916999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 mg, 12 h prior to surgery
Number of subjects: 60
Study 8916999 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 800 mg, 2 to 4 hours prior to surgery
Number of subjects: 60
Study 1863010 — intervention group
Group type: EXPERIMENTAL
Intervention: dipyridamole 75 mg three times daily and aspirin 330 mg once daily
Number of subjects: 30
Study 1863010 — intervention group
Group type: EXPERIMENTAL
Intervention: physical exercise
Number of subjects: 30
Study 1863010 — intervention group
Group type: EXPERIMENTAL
Intervention: physical exercise and dipyridamole 75 mg three times daily and aspirin 330 mg once daily
Number of subjects: 30
Study 6843620 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline with tube spacer
Number of subjects: 20
Study 6843620 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline without tube spacer (conventional aerosol)
Number of subjects: 20
Study 6843620 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31089727 — intervention group
Group type: EXPERIMENTAL
Intervention: eReferral (electronic health record-based referral)
Number of subjects: 14636
Study 27733091 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (200 U)
Number of subjects: 121
Study 27733091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 25522840 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 42
Study 23866345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 369
Study 21118796 — intervention group
Group type: EXPERIMENTAL
Intervention: Diammine silver fluoride
Number of subjects: 126
Study 21118796 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (Control)
Number of subjects: 126
Study 19880705 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0
Study 17095617 — intervention group
Group type: EXPERIMENTAL
Intervention: New agents for the treatment of acute leukemia
Number of subjects: 0
Study 17095617 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate measures for clinical benefit
Number of subjects: 0
Study 17095617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomized clinical trials
Number of subjects: 0
Study 15143375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy, education and motivation
Number of subjects: 634
Study 15143375 — intervention group
Group type: COMPARATOR
Intervention: Education and motivation
Number of subjects: 634
Study 15143375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy
Number of subjects: 634
Study 10969304 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (28 microgram/kg)
Number of subjects: 17
Study 10969304 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (8.6 microgram/kg)
Number of subjects: 17
Study 10969304 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 17
Study 8771421 — intervention group
Group type: EXPERIMENTAL
Intervention: On-the-spot escorts present throughout the procedure
Number of subjects: 206
Study 8771421 — intervention group
Group type: COMPARATOR
Intervention: Waiting-room escorts
Number of subjects: 206
Study 1299499 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg.kg‐1 L‐ornithine.HCl
Number of subjects: 12
Study 1299499 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg.kg‐1 L‐ornithine.HCl
Number of subjects: 12
Study 1299499 — intervention group
Group type: EXPERIMENTAL
Intervention: 170 mg.kg‐1 L‐ornithine.HCl
Number of subjects: 12
Study 6744203 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 120
Study 6744203 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (6 cycles of Adriamycin (45 mg/m2), vincristine (1.2 mg/m2), and cyclophosphamide (200 mg/m2 for 5 days) every 4 weeks)
Number of subjects: 120
Study 6744203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy and chemotherapy)
Number of subjects: 120
Study 6744203 — intervention group
Group type: COMPARATOR
Intervention: Levamisole immunotherapy (150 mg a day, 2 days weekly)
Number of subjects: 120
Study 31504891 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggs from hens aged 32 weeks
Number of subjects: 6048
Study 31504891 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg storage for 7 days
Number of subjects: 6048
Study 31504891 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg storage for 10 days
Number of subjects: 6048
Study 31504891 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg storage for 13 days
Number of subjects: 6048
Study 31504891 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg storage for 17 days
Number of subjects: 6048
Study 31504891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hens aged 38, 46, and 51 weeks
Number of subjects: 6048
Study 29886075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity agility program (15 sessions, 3 weeks)
Number of subjects: 72
Study 29886075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity agility program
Number of subjects: 72
Study 29886075 — intervention group
Group type: COMPARATOR
Intervention: No physical intervention control
Number of subjects: 72
Study 1564302 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute i.v. administration of erythromycin (500 mg every 8 hours for 24 hours)
Number of subjects: 1
Study 1564302 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral therapy with erythromycin (500 mg three times daily for 15 weeks)
Number of subjects: 1
Study 22576305 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia senegal barrier
Number of subjects: 60
Study 22576305 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulfate ointment
Number of subjects: 60
Study 20537151 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 296
Study 20537151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 18662628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (expired end‐tidal concentration 1%)
Number of subjects: 30
Study 18662628 — intervention group
Group type: COMPARATOR
Intervention: Placebo oxygen/air mix
Number of subjects: 30
Study 15966092 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 15966092 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 12595326 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographers reporting
Number of subjects: 400
Study 12595326 — intervention group
Group type: COMPARATOR
Intervention: Consultant radiologists reporting
Number of subjects: 400
Study 10910673 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking pregnant women
Number of subjects: 0
Study 10910673 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking pregnant women
Number of subjects: 0
Study 8964395 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 10 mg daily
Number of subjects: 72
Study 8964395 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 40 mg daily
Number of subjects: 72
Study 1889023 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol eyedrops
Number of subjects: 10
Study 1889023 — intervention group
Group type: COMPARATOR
Intervention: placebo drops
Number of subjects: 10
Study 3875389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, Methotrexate, Folinic acid rescue, and Cisplatin (VMP)
Number of subjects: 28
Study 30682445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T alone (Arm A)
Number of subjects: 49
Study 30682445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T after sensitizing radiation therapy (Arm B)
Number of subjects: 49
Study 30682445 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 49
Study 29566437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 10 mg/kg
Number of subjects: 0
Study 29566437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26991468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentoxyfylline 400 mg thrice daily for 3 weeks
Number of subjects: 110
Study 26991468 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet thrice daily for 3 weeks
Number of subjects: 110
Study 25267413 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper alpha neurofeedback (25 min session)
Number of subjects: 19
Study 25267413 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 19
Study 22569029 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg kg(‐1) following remifentanil infusion at 0.5 μg kg(‐1) min(‐1)
Number of subjects: 92
Study 22569029 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal cognitive function, MMSE score 25 or higher)
Number of subjects: 92
Study 20010613 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-alginate-containing dressing
Number of subjects: 100
Study 20010613 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study 17915162 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-NEV arm (ddI + d4T + nelfinavir)
Number of subjects: 137
Study 17915162 — intervention group
Group type: COMPARATOR
Intervention: NEV-PI arm (ddI + d4T + nevirapine)
Number of subjects: 137
Study 17915162 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-NEV arm
Number of subjects: 137
Study 17915162 — intervention group
Group type: COMPARATOR
Intervention: NEV-PI arm
Number of subjects: 137
Study 17876489 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting the tape loosely leaving a scissor tip gap between the tape and the urethra
Number of subjects: 0
Study 17876489 — intervention group
Group type: COMPARATOR
Intervention: Setting the tape actually touching the urethra and covering the tape by the adjacent pubocervicovaginal fascia with the aid of a suture
Number of subjects: 0
Study 15359898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 120
Study 15359898 — intervention group
Group type: COMPARATOR
Intervention: No-pravastatin group
Number of subjects: 120
Study 15359898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness ratio for coronary heart disease
Number of subjects: 120
Study 11419382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervening target-absent lineup exposure
Number of subjects: 160
Study 9407256 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplement (2.9 g.day-1) containing leucine, isoleucine, valine, glutamine, and carnitine
Number of subjects: 14
Study 9407256 — intervention group
Group type: COMPARATOR
Intervention: Lactose (3 g.day-1)
Number of subjects: 14
Study 8171216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg two times daily for 3 months
Number of subjects: 56
Study 8171216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 3513752 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 0
Study 3513752 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenmetrazine (25 mg)
Number of subjects: 0
Study 3513752 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine (37.5 mg)
Number of subjects: 0
Study 3513752 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 0
Study 3513752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline (75 mg)
Number of subjects: 0
Study 11491175 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment (5 days)
Number of subjects: 13
Study 11491175 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (5 days)
Number of subjects: 13
Study 30528698 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Kscore
Number of subjects: 2872
Study 30528698 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotterdam Prostate Cancer Risk Calculator (RPCRC)
Number of subjects: 2872
Study 30528698 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RPCRC and 4Kscore
Number of subjects: 2872
Study 30528698 — intervention group
Group type: COMPARATOR
Intervention: RPCRC
Number of subjects: 2872
Study 30528698 — intervention group
Group type: EXPERIMENTAL
Intervention: RPCRC-4Kscore combination
Number of subjects: 2872
Study 30107812 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbalanced randomization
Number of subjects: 148
Study 27481512 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (500/100/500)‐docetaxel (100)
Number of subjects: 2669
Study 27481512 — intervention group
Group type: COMPARATOR
Intervention: FEC (500/100/500)‐docetaxel/gemcitabine (75/2000)
Number of subjects: 2669
Study 27481512 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF application (yes)
Number of subjects: 2669
Study 27481512 — intervention group
Group type: COMPARATOR
Intervention: G-CSF application (no)
Number of subjects: 2669
Study 24736628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5 mg
Number of subjects: 173
Study 24736628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 22581064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (HCl) for >6 months (median 37 months)
Number of subjects: 483
Study 22581064 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate or no phosphate binder (Control group)
Number of subjects: 483
Study 19846796 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop intraperitoneal insulin infusion
Number of subjects: 8
Study 19846796 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal open-loop insulin delivery (control)
Number of subjects: 8
Study 18035206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg/d
Number of subjects: 24
Study 18035206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/d
Number of subjects: 24
Study 15707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 36 microg TID via Aerolizer (total daily dose 108 microg)
Number of subjects: 16
Study 15707858 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 600 microg TID via pMDI (total daily dose 1800 microg)
Number of subjects: 16
Study 15707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol and Salbutamol
Number of subjects: 16
Study 12385513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 241
Study 9951668 — intervention group
Group type: EXPERIMENTAL
Intervention: Honan intraocular pressure reducer (HIPR) applied for 10 minutes before surgery
Number of subjects: 51
Study 9951668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HIPR)
Number of subjects: 51
Study 7811178 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 40% of heart rate reserve (HRR)
Number of subjects: 40
Study 7811178 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 60% of heart rate reserve (HRR)
Number of subjects: 40
Study 7811178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study 1693496 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton red laser photocoagulation
Number of subjects: 496
Study 1693496 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 496
Study 272060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut toothbrush bristles (CP)
Number of subjects: 30
Study 272060 — intervention group
Group type: COMPARATOR
Intervention: Round ended toothbrush bristles (RP)
Number of subjects: 30
Study 31397719 — intervention group
Group type: EXPERIMENTAL
Intervention: PHIV
Number of subjects: 448
Study 31397719 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEU
Number of subjects: 448
Study 31397719 — intervention group
Group type: EXPERIMENTAL
Intervention: HUU
Number of subjects: 448
Study 30128736 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management interventions
Number of subjects: 0
Study 30128736 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality criteria for self-management interventions
Number of subjects: 0
Study 26890096 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS treatment (1 mA, 3 sessions per week for 6 weeks)
Number of subjects: 18
Study 26890096 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 18
Study 24890443 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 270
Study 24890443 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Immersion (WI)
Number of subjects: 270
Study 24890443 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 270
Study 21896676 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy assessment/intervention
Number of subjects: 186
Study 21896676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physiotherapy intervention)
Number of subjects: 186
Study 20015525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once a day added to pioglitazone 30 mg
Number of subjects: 151
Study 20015525 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day added to pioglitazone 15 mg
Number of subjects: 151
Study 18061368 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone mode of assessment
Number of subjects: 457
Study 18061368 — intervention group
Group type: COMPARATOR
Intervention: Mail mode of assessment
Number of subjects: 457
Study 18061368 — intervention group
Group type: COMPARATOR
Intervention: Web-based mode of assessment
Number of subjects: 457
Study 18061368 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeracy
Number of subjects: 457
Study 18061368 — intervention group
Group type: COMPARATOR
Intervention: Telephone, Mail, Web-based modes
Number of subjects: 457
Study 16117734 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 80
Study 16117734 — intervention group
Group type: COMPARATOR
Intervention: Exercise (Ex)
Number of subjects: 80
Study 16117734 — intervention group
Group type: COMPARATOR
Intervention: HRT+exercise (ExHRT)
Number of subjects: 80
Study 16117734 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (Co)
Number of subjects: 80
Study 14598924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive offered to the intervention group for returning the questionnaire.
Number of subjects: 2543
Study 14598924 — intervention group
Group type: COMPARATOR
Intervention: No incentive offered to the control group.
Number of subjects: 2543
Study 14598924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive offered to the intervention group.
Number of subjects: 2543
Study 11169057 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MU recombinant interferon beta-1a, three times per week (n=11)
Number of subjects: 21
Study 11169057 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 MU recombinant interferon beta-1a, three times per week (n=10)
Number of subjects: 21
Study 11169057 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both doses)
Number of subjects: 21
Study 8867263 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine 0.5 mg/kg over 20 min
Number of subjects: 117
Study 8867263 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine 1 mg/kg over 10 min
Number of subjects: 117
Study 8867263 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients did not receive phentolamine)
Number of subjects: 117
Study 1516995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialytic ultrafiltration (DUF)
Number of subjects: 18
Study 1516995 — intervention group
Group type: COMPARATOR
Intervention: Large paracentesis (LP)
Number of subjects: 18
Study 6367617 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-17 beta 4 mg daily
Number of subjects: 50
Study 6367617 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-17 beta 2 mg daily
Number of subjects: 50
Study 6367617 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-17 beta
Number of subjects: 50
Study 30735912 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg)
Number of subjects: 27
Study 30735912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27